"Anti-Retroviral Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used to treat RETROVIRIDAE INFECTIONS.
| Descriptor ID |
D044966
|
| MeSH Number(s) |
D27.505.954.122.388.077
|
| Concept/Terms |
Anti-Retroviral Agents- Anti-Retroviral Agents
- Agents, Anti-Retroviral
- Anti Retroviral Agents
- Antiretroviral Agents
- Agents, Antiretroviral
|
Below are MeSH descriptors whose meaning is more general than "Anti-Retroviral Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-Retroviral Agents".
This graph shows the total number of publications written about "Anti-Retroviral Agents" by people in this website by year, and whether "Anti-Retroviral Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 2 | 0 | 2 |
| 2004 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2010 | 2 | 0 | 2 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 1 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 5 | 5 |
| 2018 | 1 | 2 | 3 |
| 2019 | 1 | 0 | 1 |
| 2020 | 2 | 0 | 2 |
| 2021 | 0 | 2 | 2 |
| 2022 | 1 | 1 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anti-Retroviral Agents" by people in Profiles.
-
The human gut microbiome and its metabolic pathway dynamics before and during HIV antiretroviral therapy. Microbiol Spectr. 2025 Aug 05; 13(8):e0220524.
-
Gut microbiota differences linked to weight gain and ART in people living with HIV are enterotype specific and minor compared to the large differences linked to sexual behavior. Front Cell Infect Microbiol. 2025; 15:1568352.
-
The impact of HIV antiretroviral therapy on gut microbiota: the need for well-designed longitudinal studies. J Infect Dev Ctries. 2024 Oct 31; 18(10):1461-1473.
-
Treatment options for severe or refractory mpox virus infection in patients with advanced HIV. Int J STD AIDS. 2023 05; 34(6):366-373.
-
"When you have an immune disease like HIV and there is a pandemic, you still have to pay your bills": COVID-19-related challenges among people living with HIV and lessons for care delivery. AIDS Care. 2022 11; 34(11):1405-1412.
-
Antiretroviral therapy timing impacts latent tuberculosis infection reactivation in a Mycobacterium tuberculosis/SIV coinfection model. J Clin Invest. 2022 02 01; 132(3).
-
Alveolar macrophages from persons living with HIV show impaired epigenetic response to Mycobacterium tuberculosis. J Clin Invest. 2021 11 15; 131(22).
-
Pharmacokinetics and safety of maraviroc in neonates. AIDS. 2021 03 01; 35(3):419-427.
-
Patterns of Exposure to Socio-structural Stressors and HIV Care Engagement Among Transgender Women of Color. AIDS Behav. 2020 Nov; 24(11):3155-3163.
-
Antiretroviral therapy does not reduce tuberculosis reactivation in a tuberculosis-HIV coinfection model. J Clin Invest. 2020 10 01; 130(10):5171-5179.